

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.org) on May 16, 2024

Met (D1C2) XP Rabbit mAb

RRID:AB_10858224

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 8198, RRID:AB_10858224)

Antibody Information

URL: http://antibodyregistry.org/AB_10858224

Proper Citation: (Cell Signaling Technology Cat# 8198, RRID:AB_10858224)

Target Antigen: Met

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-Bond, IHC-P, IHC-F, IF-IC, F. Consolidation on 11/2018: AB_10858224, AB_10860590.

Antibody Name: Met (D1C2) XP Rabbit mAb

Description: This monoclonal targets Met

Target Organism: human

Clone ID: D1C2

Antibody ID: AB_10858224

Vendor: Cell Signaling Technology

Catalog Number: 8198

Ratings and Alerts

No rating or validation information has been found for Met (D1C2) XP Rabbit mAb.

No alerts have been found for Met (D1C2) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. *Cell reports. Medicine*, 5(2), 101388.

Li X, et al. (2024) Colorectal cancer cells secreting DKK4 transform fibroblasts to promote tumour metastasis. *Oncogene*.

Vallés-Martí A, et al. (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. *Cell reports*, 42(6), 112581.

Choi YR, et al. (2023) Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. *British journal of cancer*.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. *Cell reports. Medicine*, 4(8), 101142.

Lin ZS, et al. (2023) EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression. *eLife*, 12.

Yu J, et al. (2023) VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. *EBioMedicine*, 89, 104451.

Wu F, et al. (2023) Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes. *EBioMedicine*, 87, 104410.

Pal AS, et al. (2022) Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET. *Cancer research*, 82(8), 1534.

Bahcall M, et al. (2022) Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. *Molecular cancer therapeutics*, 21(2), 322.

Jikuya R, et al. (2022) Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. *iScience*, 25(6), 104463.

da Silva-Oliveira RJ, et al. (2022) Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGFR Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. *International journal of molecular sciences*, 23(14).

Shao WQ, et al. (2022) Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. *Cell reports*, 39(3), 110712.

Jonker PKC, et al. (2022) Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection. *European journal of nuclear medicine and molecular imaging*, 49(10), 3557.

Pathmanathan S, et al. (2022) B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer. *iScience*, 25(11), 105419.

Li H, et al. (2022) Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis. *Cell reports*, 41(12), 111834.

Kim M, et al. (2021) A MET-PTPRK kinase-phosphatase rheostat controls ZNRF3 and Wnt signaling. *eLife*, 10.

Huang L, et al. (2021) Targeting Pan-ETS Factors Inhibits Melanoma Progression. *Cancer research*, 81(8), 2071.

Low JL, et al. (2021) Molecular docking-aided identification of small molecule inhibitors targeting β -catenin-TCF4 interaction. *iScience*, 24(6), 102544.

Wang H, et al. (2021) Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. *Cell reports*, 34(8), 108765.